| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spike Glycoprotein, Coronavirus | 14 | 2025 | 218 | 1.640 |
Why?
|
| Vaccines | 12 | 2024 | 385 | 1.520 |
Why?
|
| Alanine Racemase | 11 | 2011 | 11 | 1.280 |
Why?
|
| Viral Vaccines | 7 | 2021 | 316 | 0.890 |
Why?
|
| Chagas Disease | 10 | 2024 | 314 | 0.860 |
Why?
|
| Recombinant Proteins | 17 | 2023 | 1311 | 0.850 |
Why?
|
| Lyme Disease | 4 | 2025 | 34 | 0.790 |
Why?
|
| Pandemics | 7 | 2022 | 1157 | 0.760 |
Why?
|
| Vaccination | 11 | 2025 | 1036 | 0.690 |
Why?
|
| Bacterial Proteins | 6 | 2025 | 931 | 0.680 |
Why?
|
| Adjuvants, Immunologic | 9 | 2025 | 392 | 0.680 |
Why?
|
| Protozoan Vaccines | 6 | 2024 | 99 | 0.630 |
Why?
|
| Borrelia burgdorferi | 3 | 2025 | 18 | 0.620 |
Why?
|
| Vaccines, Synthetic | 8 | 2022 | 320 | 0.590 |
Why?
|
| Transcription, Genetic | 1 | 2024 | 1396 | 0.580 |
Why?
|
| Coronavirus Infections | 6 | 2021 | 365 | 0.580 |
Why?
|
| RNA, Messenger | 2 | 2024 | 2575 | 0.580 |
Why?
|
| Trypanosoma cruzi | 6 | 2021 | 256 | 0.490 |
Why?
|
| Saccharomycetales | 5 | 2021 | 38 | 0.470 |
Why?
|
| Neglected Diseases | 2 | 2015 | 152 | 0.470 |
Why?
|
| Pseudomonas aeruginosa | 4 | 2003 | 174 | 0.460 |
Why?
|
| Universities | 1 | 2015 | 122 | 0.450 |
Why?
|
| Leishmaniasis Vaccines | 3 | 2020 | 20 | 0.440 |
Why?
|
| Antibodies, Viral | 11 | 2025 | 1166 | 0.420 |
Why?
|
| Developing Countries | 2 | 2016 | 303 | 0.420 |
Why?
|
| Drug Discovery | 1 | 2015 | 178 | 0.420 |
Why?
|
| Animals | 38 | 2025 | 34278 | 0.420 |
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 3 | 2025 | 22 | 0.400 |
Why?
|
| Cost-Benefit Analysis | 4 | 2024 | 543 | 0.390 |
Why?
|
| Gene Expression | 5 | 2021 | 1500 | 0.380 |
Why?
|
| Vaccines, Subunit | 2 | 2024 | 72 | 0.380 |
Why?
|
| Ixodes | 2 | 2022 | 21 | 0.370 |
Why?
|
| Protozoan Proteins | 3 | 2018 | 135 | 0.370 |
Why?
|
| Escherichia coli | 9 | 2024 | 981 | 0.370 |
Why?
|
| Mice, Inbred BALB C | 10 | 2025 | 1018 | 0.350 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 379 | 0.340 |
Why?
|
| Lyme Disease Vaccines | 3 | 2025 | 11 | 0.330 |
Why?
|
| Phlebotomus | 2 | 2020 | 14 | 0.320 |
Why?
|
| Antibodies, Neutralizing | 9 | 2024 | 515 | 0.310 |
Why?
|
| Genes, Bacterial | 3 | 2001 | 216 | 0.300 |
Why?
|
| Antigens, Protozoan | 3 | 2024 | 80 | 0.300 |
Why?
|
| Serratia marcescens | 2 | 1999 | 11 | 0.300 |
Why?
|
| Immunoassay | 4 | 2022 | 133 | 0.300 |
Why?
|
| Saccharomyces cerevisiae | 5 | 2023 | 403 | 0.290 |
Why?
|
| Betacoronavirus | 3 | 2020 | 286 | 0.290 |
Why?
|
| Streptococcus pneumoniae | 2 | 2011 | 389 | 0.290 |
Why?
|
| Protein Domains | 7 | 2025 | 249 | 0.280 |
Why?
|
| DNA | 3 | 2024 | 1444 | 0.280 |
Why?
|
| Ascariasis | 2 | 2020 | 73 | 0.270 |
Why?
|
| Immunoglobulin G | 5 | 2022 | 810 | 0.270 |
Why?
|
| Amino Acid Sequence | 11 | 2021 | 2560 | 0.270 |
Why?
|
| Cloning, Molecular | 7 | 2021 | 785 | 0.270 |
Why?
|
| Humans | 53 | 2025 | 130931 | 0.270 |
Why?
|
| Mice | 20 | 2025 | 18410 | 0.260 |
Why?
|
| Alum Compounds | 3 | 2022 | 42 | 0.260 |
Why?
|
| Aptamers, Nucleotide | 3 | 2013 | 39 | 0.260 |
Why?
|
| Immunoglobulin Fc Fragments | 2 | 2025 | 28 | 0.260 |
Why?
|
| Immunoglobulin A | 2 | 2025 | 211 | 0.260 |
Why?
|
| Schistosomiasis | 3 | 2016 | 52 | 0.260 |
Why?
|
| Nanoparticles | 3 | 2015 | 292 | 0.260 |
Why?
|
| Hookworm Infections | 3 | 2016 | 125 | 0.250 |
Why?
|
| Mycobacterium tuberculosis | 4 | 2011 | 422 | 0.240 |
Why?
|
| Severe Acute Respiratory Syndrome | 3 | 2020 | 39 | 0.230 |
Why?
|
| Bacteriophage M13 | 2 | 2015 | 17 | 0.230 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2024 | 122 | 0.230 |
Why?
|
| Leishmaniasis | 2 | 2016 | 40 | 0.230 |
Why?
|
| Antibodies, Protozoan | 4 | 2018 | 99 | 0.230 |
Why?
|
| Molecular Sequence Data | 10 | 2013 | 3610 | 0.230 |
Why?
|
| Aluminum Hydroxide | 2 | 2022 | 40 | 0.220 |
Why?
|
| Biological Assay | 2 | 2015 | 108 | 0.220 |
Why?
|
| Polymerase Chain Reaction | 4 | 2012 | 1490 | 0.220 |
Why?
|
| Vaccination Coverage | 2 | 2022 | 37 | 0.220 |
Why?
|
| Markov Chains | 1 | 2024 | 100 | 0.210 |
Why?
|
| Computer Simulation | 3 | 2025 | 686 | 0.210 |
Why?
|
| RNA Caps | 1 | 2024 | 28 | 0.210 |
Why?
|
| Salivary Proteins and Peptides | 2 | 2020 | 18 | 0.210 |
Why?
|
| Transduction, Genetic | 1 | 2024 | 280 | 0.200 |
Why?
|
| Bacteriophages | 2 | 2015 | 93 | 0.200 |
Why?
|
| Immunity, Innate | 2 | 2024 | 409 | 0.200 |
Why?
|
| Insect Proteins | 2 | 2020 | 99 | 0.200 |
Why?
|
| Adaptive Immunity | 1 | 2024 | 100 | 0.200 |
Why?
|
| Genetic Engineering | 2 | 2018 | 162 | 0.200 |
Why?
|
| Immunoglobulin E | 2 | 2015 | 224 | 0.200 |
Why?
|
| Cost of Illness | 1 | 2025 | 289 | 0.200 |
Why?
|
| Borrelia burgdorferi Group | 1 | 2022 | 4 | 0.190 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2025 | 690 | 0.190 |
Why?
|
| Viruses | 2 | 2015 | 118 | 0.190 |
Why?
|
| Ascaris suum | 2 | 2020 | 32 | 0.190 |
Why?
|
| Antigens, Helminth | 3 | 2020 | 187 | 0.190 |
Why?
|
| Models, Animal | 1 | 2024 | 459 | 0.180 |
Why?
|
| Clinical Trials as Topic | 4 | 2021 | 1134 | 0.180 |
Why?
|
| Transfection | 1 | 2024 | 960 | 0.180 |
Why?
|
| Helminth Proteins | 2 | 2020 | 104 | 0.180 |
Why?
|
| Mycobacterium smegmatis | 2 | 2014 | 8 | 0.180 |
Why?
|
| Trichuriasis | 1 | 2022 | 31 | 0.180 |
Why?
|
| Zebrafish | 1 | 2024 | 422 | 0.180 |
Why?
|
| Mycobacterium avium | 1 | 2001 | 18 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2014 | 339 | 0.170 |
Why?
|
| Communicable Disease Control | 2 | 2020 | 142 | 0.170 |
Why?
|
| Borrelia | 1 | 2022 | 81 | 0.170 |
Why?
|
| HIV-1 | 1 | 2024 | 477 | 0.170 |
Why?
|
| Acinetobacter Infections | 1 | 2021 | 36 | 0.170 |
Why?
|
| Antibodies, Helminth | 2 | 2020 | 131 | 0.170 |
Why?
|
| Acinetobacter baumannii | 1 | 2021 | 47 | 0.160 |
Why?
|
| Leishmania | 1 | 2020 | 33 | 0.160 |
Why?
|
| RNA, Ribosomal, 5S | 2 | 2010 | 7 | 0.160 |
Why?
|
| Pichia | 2 | 2017 | 56 | 0.160 |
Why?
|
| Rhodococcus | 1 | 2020 | 2 | 0.160 |
Why?
|
| Intention | 1 | 2021 | 100 | 0.160 |
Why?
|
| Sequence Alignment | 6 | 2017 | 593 | 0.160 |
Why?
|
| Immunoglobulin M | 2 | 2018 | 213 | 0.160 |
Why?
|
| Pepsin A | 1 | 2019 | 11 | 0.160 |
Why?
|
| Aspartic Acid Proteases | 1 | 2019 | 9 | 0.160 |
Why?
|
| Cysteine | 2 | 2017 | 139 | 0.160 |
Why?
|
| Health Resources | 1 | 2021 | 128 | 0.150 |
Why?
|
| Computational Biology | 2 | 2022 | 870 | 0.150 |
Why?
|
| Calcium-Binding Proteins | 2 | 2017 | 330 | 0.150 |
Why?
|
| Molecular Sequence Annotation | 1 | 2020 | 152 | 0.150 |
Why?
|
| Endodeoxyribonucleases | 1 | 1999 | 45 | 0.150 |
Why?
|
| Ultraviolet Rays | 1 | 2019 | 194 | 0.150 |
Why?
|
| Antibodies, Catalytic | 1 | 2018 | 7 | 0.150 |
Why?
|
| Endoribonucleases | 1 | 1999 | 84 | 0.150 |
Why?
|
| Genome, Bacterial | 1 | 2020 | 209 | 0.140 |
Why?
|
| Administration, Intranasal | 3 | 2024 | 130 | 0.140 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 321 | 0.140 |
Why?
|
| Endonucleases | 1 | 1998 | 50 | 0.140 |
Why?
|
| Biomedical Research | 4 | 2016 | 555 | 0.140 |
Why?
|
| Biotinylation | 2 | 2015 | 20 | 0.140 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 355 | 0.140 |
Why?
|
| Molecular Weight | 3 | 2020 | 298 | 0.140 |
Why?
|
| Superantigens | 1 | 2017 | 20 | 0.130 |
Why?
|
| Chemistry Techniques, Analytical | 1 | 2017 | 8 | 0.130 |
Why?
|
| Fluorometry | 1 | 2017 | 25 | 0.130 |
Why?
|
| Alanine | 2 | 2007 | 162 | 0.130 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2014 | 299 | 0.130 |
Why?
|
| Th2 Cells | 1 | 2017 | 186 | 0.120 |
Why?
|
| Phospholipids | 1 | 2017 | 102 | 0.120 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2020 | 381 | 0.120 |
Why?
|
| Temperature | 2 | 2017 | 294 | 0.120 |
Why?
|
| Antigens, Viral | 1 | 2018 | 396 | 0.120 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 2016 | 12 | 0.120 |
Why?
|
| Crystallization | 3 | 2007 | 83 | 0.120 |
Why?
|
| Aptamers, Peptide | 1 | 2015 | 4 | 0.120 |
Why?
|
| Leishmania donovani | 1 | 2016 | 24 | 0.120 |
Why?
|
| Penicillin-Binding Proteins | 1 | 2015 | 14 | 0.120 |
Why?
|
| Mutant Proteins | 1 | 2016 | 113 | 0.120 |
Why?
|
| Drug Industry | 1 | 2015 | 48 | 0.120 |
Why?
|
| Organizations, Nonprofit | 1 | 2015 | 27 | 0.120 |
Why?
|
| Crystallography, X-Ray | 5 | 2025 | 365 | 0.120 |
Why?
|
| Magnetite Nanoparticles | 1 | 2015 | 8 | 0.110 |
Why?
|
| Specimen Handling | 1 | 2016 | 148 | 0.110 |
Why?
|
| World Health Organization | 1 | 2015 | 115 | 0.110 |
Why?
|
| Mass Spectrometry | 3 | 2012 | 357 | 0.110 |
Why?
|
| Helminthiasis | 1 | 2016 | 83 | 0.110 |
Why?
|
| Orotidine-5'-Phosphate Decarboxylase | 1 | 1994 | 3 | 0.110 |
Why?
|
| Alkaline Phosphatase | 1 | 2015 | 94 | 0.110 |
Why?
|
| Ascorbic Acid | 1 | 2015 | 72 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 530 | 0.110 |
Why?
|
| Amino Acid Isomerases | 1 | 2014 | 4 | 0.110 |
Why?
|
| Models, Molecular | 5 | 2025 | 1084 | 0.110 |
Why?
|
| Enzyme Inhibitors | 2 | 2011 | 565 | 0.110 |
Why?
|
| Malaria | 1 | 2015 | 99 | 0.110 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2014 | 15 | 0.110 |
Why?
|
| Goals | 1 | 2015 | 125 | 0.110 |
Why?
|
| Biosensing Techniques | 2 | 2012 | 74 | 0.110 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2014 | 22 | 0.110 |
Why?
|
| Sensitivity and Specificity | 5 | 2022 | 2122 | 0.110 |
Why?
|
| Genes, Essential | 1 | 2014 | 43 | 0.110 |
Why?
|
| RNA | 2 | 2024 | 531 | 0.110 |
Why?
|
| Cardiomyopathies | 1 | 2019 | 515 | 0.110 |
Why?
|
| Dengue Virus | 2 | 2012 | 134 | 0.110 |
Why?
|
| Gold | 1 | 2014 | 55 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 224 | 0.110 |
Why?
|
| Complement Factor H | 2 | 2025 | 24 | 0.100 |
Why?
|
| Levivirus | 1 | 2013 | 3 | 0.100 |
Why?
|
| Immunization | 3 | 2022 | 307 | 0.100 |
Why?
|
| Encephalitis Virus, Japanese | 1 | 2013 | 22 | 0.100 |
Why?
|
| Tropical Medicine | 1 | 2015 | 104 | 0.100 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1994 | 239 | 0.100 |
Why?
|
| Immunity, Mucosal | 2 | 2025 | 90 | 0.100 |
Why?
|
| Genetic Vectors | 3 | 2024 | 900 | 0.100 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2011 | 623 | 0.100 |
Why?
|
| Chemical Precipitation | 1 | 2012 | 11 | 0.100 |
Why?
|
| Technology | 2 | 2024 | 70 | 0.100 |
Why?
|
| beta-Globins | 1 | 2012 | 9 | 0.100 |
Why?
|
| Bacteriophage lambda | 1 | 2012 | 26 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 5 | 2021 | 723 | 0.100 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2012 | 37 | 0.100 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2015 | 236 | 0.100 |
Why?
|
| Female | 15 | 2025 | 70755 | 0.100 |
Why?
|
| Peroxidase | 1 | 2012 | 62 | 0.100 |
Why?
|
| Fermentation | 3 | 2020 | 67 | 0.090 |
Why?
|
| Oligonucleotides | 1 | 2012 | 96 | 0.090 |
Why?
|
| Caliciviridae Infections | 1 | 2015 | 289 | 0.090 |
Why?
|
| Dimerization | 3 | 2007 | 139 | 0.090 |
Why?
|
| Cricetulus | 2 | 2025 | 88 | 0.090 |
Why?
|
| Anemia | 1 | 2016 | 354 | 0.090 |
Why?
|
| CHO Cells | 2 | 2025 | 149 | 0.090 |
Why?
|
| DNA, Bacterial | 2 | 2007 | 492 | 0.090 |
Why?
|
| Deoxyribonucleases | 1 | 2011 | 19 | 0.090 |
Why?
|
| Poverty | 1 | 2015 | 451 | 0.090 |
Why?
|
| Norovirus | 1 | 2015 | 288 | 0.090 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2025 | 429 | 0.090 |
Why?
|
| United States | 6 | 2025 | 11718 | 0.090 |
Why?
|
| Nucleic Acids | 1 | 2011 | 26 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 1999 | 1611 | 0.090 |
Why?
|
| DNA, Catalytic | 1 | 2010 | 4 | 0.090 |
Why?
|
| Lung | 3 | 2025 | 1566 | 0.080 |
Why?
|
| High-Throughput Screening Assays | 1 | 2011 | 117 | 0.080 |
Why?
|
| Protein Conformation | 3 | 2019 | 807 | 0.080 |
Why?
|
| Staining and Labeling | 3 | 2017 | 170 | 0.080 |
Why?
|
| Antibody Formation | 2 | 2022 | 268 | 0.080 |
Why?
|
| Macaca mulatta | 2 | 2021 | 496 | 0.080 |
Why?
|
| Binding Sites | 4 | 2022 | 1200 | 0.080 |
Why?
|
| Rosaniline Dyes | 1 | 2009 | 5 | 0.080 |
Why?
|
| Antigens, Bacterial | 2 | 2025 | 319 | 0.070 |
Why?
|
| Bacillus anthracis | 1 | 2009 | 39 | 0.070 |
Why?
|
| Viral Load | 2 | 2021 | 405 | 0.070 |
Why?
|
| Protein Stability | 2 | 2020 | 165 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2022 | 455 | 0.070 |
Why?
|
| Epitopes | 2 | 2022 | 432 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2011 | 265 | 0.070 |
Why?
|
| Leishmaniasis, Cutaneous | 2 | 2020 | 48 | 0.070 |
Why?
|
| Base Sequence | 2 | 2007 | 2781 | 0.070 |
Why?
|
| Protein Binding | 3 | 2021 | 1705 | 0.070 |
Why?
|
| Genetic Complementation Test | 1 | 2007 | 87 | 0.070 |
Why?
|
| Gene Deletion | 3 | 2014 | 772 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2021 | 844 | 0.060 |
Why?
|
| Freeze Drying | 1 | 2024 | 15 | 0.060 |
Why?
|
| B-Lymphocytes | 2 | 2018 | 526 | 0.060 |
Why?
|
| Fluorescent Dyes | 2 | 2017 | 251 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2024 | 186 | 0.050 |
Why?
|
| Proteins | 2 | 2023 | 1025 | 0.050 |
Why?
|
| Conserved Sequence | 1 | 2005 | 280 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2024 | 226 | 0.050 |
Why?
|
| Imines | 1 | 2003 | 10 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2024 | 365 | 0.050 |
Why?
|
| Fluorescence | 2 | 2017 | 97 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2024 | 167 | 0.050 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2024 | 117 | 0.050 |
Why?
|
| HIV Infections | 1 | 2015 | 2031 | 0.050 |
Why?
|
| Cycloserine | 1 | 2003 | 23 | 0.050 |
Why?
|
| Protein Multimerization | 2 | 2016 | 150 | 0.050 |
Why?
|
| Staphylococcal Protein A | 1 | 2022 | 7 | 0.050 |
Why?
|
| Nucleoproteins | 1 | 2022 | 21 | 0.050 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2003 | 38 | 0.050 |
Why?
|
| Antigens | 1 | 2023 | 148 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2025 | 425 | 0.050 |
Why?
|
| Luciferases | 1 | 2022 | 127 | 0.050 |
Why?
|
| Mice, Inbred AKR | 1 | 2022 | 16 | 0.050 |
Why?
|
| Trichuris | 1 | 2022 | 26 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2020 | 391 | 0.050 |
Why?
|
| HEK293 Cells | 1 | 2024 | 802 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2022 | 124 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2022 | 88 | 0.040 |
Why?
|
| Masks | 1 | 2022 | 38 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2025 | 400 | 0.040 |
Why?
|
| Rabbits | 1 | 2022 | 632 | 0.040 |
Why?
|
| Vibrio cholerae | 1 | 2021 | 33 | 0.040 |
Why?
|
| Models, Economic | 1 | 2021 | 57 | 0.040 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2021 | 35 | 0.040 |
Why?
|
| Cholera | 1 | 2021 | 38 | 0.040 |
Why?
|
| Bacterial Vaccines | 1 | 2021 | 104 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2007 | 1741 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2022 | 155 | 0.040 |
Why?
|
| Malaria, Falciparum | 1 | 2021 | 70 | 0.040 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2021 | 132 | 0.040 |
Why?
|
| Chickens | 2 | 2013 | 285 | 0.040 |
Why?
|
| Antibodies | 1 | 2022 | 357 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2022 | 199 | 0.040 |
Why?
|
| Plasmodium falciparum | 1 | 2021 | 96 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2021 | 188 | 0.040 |
Why?
|
| Protein Structure, Quaternary | 2 | 2011 | 93 | 0.040 |
Why?
|
| DNA Primers | 1 | 2001 | 609 | 0.040 |
Why?
|
| Disease Eradication | 1 | 2020 | 40 | 0.040 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2021 | 149 | 0.040 |
Why?
|
| Latin America | 1 | 2020 | 101 | 0.040 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2019 | 41 | 0.040 |
Why?
|
| Mexico | 1 | 2020 | 197 | 0.040 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2020 | 153 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2020 | 102 | 0.040 |
Why?
|
| Eosinophils | 1 | 2020 | 125 | 0.040 |
Why?
|
| Operon | 1 | 1999 | 49 | 0.040 |
Why?
|
| Soil | 1 | 2020 | 76 | 0.040 |
Why?
|
| Blotting, Southern | 1 | 1999 | 208 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 172 | 0.040 |
Why?
|
| Nitriles | 1 | 2020 | 164 | 0.040 |
Why?
|
| Nitroimidazoles | 1 | 2019 | 48 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2025 | 1006 | 0.040 |
Why?
|
| Internet | 1 | 2022 | 417 | 0.040 |
Why?
|
| Protein Folding | 1 | 2019 | 215 | 0.040 |
Why?
|
| Monocytes | 1 | 2020 | 334 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 496 | 0.040 |
Why?
|
| Biotechnology | 1 | 1998 | 59 | 0.030 |
Why?
|
| Plasmids | 1 | 1999 | 455 | 0.030 |
Why?
|
| Freezing | 1 | 2017 | 26 | 0.030 |
Why?
|
| Protein Precursors | 1 | 1998 | 148 | 0.030 |
Why?
|
| Phylogeny | 1 | 2020 | 706 | 0.030 |
Why?
|
| Sequence Analysis | 1 | 2017 | 51 | 0.030 |
Why?
|
| Cholera Toxin | 1 | 2017 | 43 | 0.030 |
Why?
|
| Industrial Microbiology | 1 | 2017 | 8 | 0.030 |
Why?
|
| Interleukin-5 | 1 | 2017 | 49 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2017 | 140 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2017 | 144 | 0.030 |
Why?
|
| Staphylococcus aureus | 2 | 2015 | 483 | 0.030 |
Why?
|
| Software | 1 | 2022 | 752 | 0.030 |
Why?
|
| Parasite Load | 1 | 2016 | 31 | 0.030 |
Why?
|
| Toll-Like Receptors | 1 | 2017 | 82 | 0.030 |
Why?
|
| Larva | 1 | 2017 | 252 | 0.030 |
Why?
|
| Serine | 1 | 2017 | 163 | 0.030 |
Why?
|
| Cell Line | 1 | 2021 | 2596 | 0.030 |
Why?
|
| Fatty Acid Transport Proteins | 1 | 2016 | 11 | 0.030 |
Why?
|
| Schistosoma mansoni | 1 | 2016 | 24 | 0.030 |
Why?
|
| Psychodidae | 1 | 2016 | 12 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2016 | 56 | 0.030 |
Why?
|
| Schistosoma haematobium | 1 | 2016 | 17 | 0.030 |
Why?
|
| Chromatography, Gel | 1 | 2016 | 79 | 0.030 |
Why?
|
| Dynamic Light Scattering | 1 | 2016 | 9 | 0.030 |
Why?
|
| Tetraspanins | 1 | 2016 | 32 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2017 | 413 | 0.030 |
Why?
|
| Mutation | 2 | 2017 | 6144 | 0.030 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2016 | 20 | 0.030 |
Why?
|
| Anthelmintics | 1 | 2016 | 55 | 0.030 |
Why?
|
| Primates | 1 | 2016 | 82 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2018 | 353 | 0.030 |
Why?
|
| Necator americanus | 1 | 2016 | 91 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2016 | 333 | 0.030 |
Why?
|
| Holmium | 1 | 2015 | 10 | 0.030 |
Why?
|
| Asia, Southeastern | 1 | 2015 | 22 | 0.030 |
Why?
|
| Glutathione Transferase | 1 | 2016 | 145 | 0.030 |
Why?
|
| Cytokines | 1 | 2021 | 1340 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 357 | 0.030 |
Why?
|
| Dogs | 1 | 2016 | 623 | 0.030 |
Why?
|
| Pyridoxal Phosphate | 2 | 2005 | 12 | 0.030 |
Why?
|
| Carbocyanines | 1 | 2014 | 10 | 0.030 |
Why?
|
| Peptidoglycan | 1 | 2014 | 21 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 1225 | 0.030 |
Why?
|
| Diffusion | 1 | 2014 | 60 | 0.030 |
Why?
|
| Porosity | 1 | 2014 | 43 | 0.030 |
Why?
|
| Cell Wall | 1 | 2014 | 41 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1994 | 255 | 0.030 |
Why?
|
| Surface Plasmon Resonance | 1 | 2014 | 54 | 0.030 |
Why?
|
| Hydrogen Bonding | 2 | 2005 | 83 | 0.030 |
Why?
|
| Gadolinium | 1 | 2015 | 110 | 0.030 |
Why?
|
| Lectins | 1 | 2014 | 49 | 0.030 |
Why?
|
| Nanotechnology | 1 | 2014 | 50 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2950 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2016 | 542 | 0.030 |
Why?
|
| Microfluidics | 1 | 2014 | 30 | 0.030 |
Why?
|
| DNA, Single-Stranded | 1 | 2014 | 72 | 0.030 |
Why?
|
| Culture Media | 1 | 2014 | 174 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 2021 | 2558 | 0.030 |
Why?
|
| Nanostructures | 1 | 2014 | 64 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2015 | 350 | 0.030 |
Why?
|
| Metal Nanoparticles | 1 | 2014 | 55 | 0.030 |
Why?
|
| Horseradish Peroxidase | 1 | 2013 | 14 | 0.030 |
Why?
|
| Light | 1 | 2014 | 174 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 199 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 2014 | 209 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 790 | 0.020 |
Why?
|
| Serum Albumin, Bovine | 1 | 2013 | 53 | 0.020 |
Why?
|
| Muramidase | 1 | 2013 | 89 | 0.020 |
Why?
|
| Hemin | 1 | 2012 | 14 | 0.020 |
Why?
|
| G-Quadruplexes | 1 | 2012 | 11 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 1523 | 0.020 |
Why?
|
| Limit of Detection | 1 | 2012 | 74 | 0.020 |
Why?
|
| Disease Progression | 1 | 2019 | 2191 | 0.020 |
Why?
|
| Gastroenteritis | 1 | 2015 | 316 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 1768 | 0.020 |
Why?
|
| Anomura | 1 | 2011 | 2 | 0.020 |
Why?
|
| Durapatite | 1 | 2011 | 11 | 0.020 |
Why?
|
| Chromatography | 1 | 2011 | 35 | 0.020 |
Why?
|
| Iron | 1 | 2015 | 305 | 0.020 |
Why?
|
| Male | 3 | 2024 | 64823 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 3067 | 0.020 |
Why?
|
| Cattle | 1 | 2013 | 540 | 0.020 |
Why?
|
| Heart | 1 | 2016 | 674 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 896 | 0.020 |
Why?
|
| Alanine Dehydrogenase | 1 | 2011 | 1 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2011 | 85 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2011 | 285 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2011 | 159 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 4008 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 237 | 0.020 |
Why?
|
| Peptides | 1 | 2014 | 835 | 0.020 |
Why?
|
| Peptide Fragments | 2 | 2005 | 776 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2011 | 452 | 0.020 |
Why?
|
| Drug Design | 1 | 2011 | 165 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 10040 | 0.020 |
Why?
|
| Structural Homology, Protein | 1 | 2009 | 27 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2011 | 694 | 0.020 |
Why?
|
| Kinetics | 1 | 2011 | 1101 | 0.020 |
Why?
|
| Chorioallantoic Membrane | 1 | 2009 | 12 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 2009 | 179 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2009 | 204 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 7558 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 1217 | 0.020 |
Why?
|
| Adolescent | 1 | 2024 | 20814 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 4681 | 0.010 |
Why?
|
| Electrons | 1 | 2005 | 25 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2005 | 81 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 12858 | 0.010 |
Why?
|
| Infant | 1 | 2020 | 13210 | 0.010 |
Why?
|
| Geobacillus stearothermophilus | 1 | 2003 | 2 | 0.010 |
Why?
|
| Middle Aged | 1 | 2024 | 28735 | 0.010 |
Why?
|
| Adult | 1 | 2024 | 31541 | 0.010 |
Why?
|
| Aged | 1 | 2022 | 21134 | 0.010 |
Why?
|
| Chromatography, Thin Layer | 1 | 2003 | 43 | 0.010 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2003 | 32 | 0.010 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2003 | 42 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 2636 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2003 | 578 | 0.010 |
Why?
|
| Time Factors | 1 | 2007 | 6275 | 0.010 |
Why?
|